Toralizumab

N/A

Report date: 2022/05/25 17:36:12

Base Information

Drug NameToralizumab
Drug Alias Name托利珠单抗Anti-T-BAM - IDECIDEC 131E 6040Anti-CD40L - IDEC +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD40 ligand inhibitors
TargetsCD40 ligand
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisLupus Erythematosus, Systemic +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen IncSeikagaku
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeikagakuBiogen IncEisai Co Ltd
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesPsoriasisLupus Erythematosus, Systemic +[7] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG